CD4 and diffuse large B-cell lymphoma: DLBCL patients with the percentage of PD‐1‐positive CD4+ T cells ≥30.25% (n = 10) demonstrated significantly lower EFS and OS than patients with PD‐1+ CD4+ T cells <30.25% (n = 50; P < 0.05) (Fig. 6).